Enanta declines option on AbbVie-partnered hepatitis C candidate
This article was originally published in Scrip
Executive Summary
Just weeks after Novartis abandoned hepatitis C and returned all rights to EDP239, an NS5A inhibitor currently in Phase I to Enanta Pharmaceuticals (scripintelligence.com, 2 October 2014), the smaller company has decided not to exercise its co-development option for AbbVie's ABT-493.